Otsuka’s ADHD approval opens up new drug class with $615M opportunity
Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.
Otsuka’s ADHD approval opens up new drug class with $615M opportunity Read More »
